TOPLINE: In a retrospective study, switching to bimekizumab after the failure of secondary interleukin (IL)-17 inhibitors demonstrated comparable drug survival to switching to IL-23 inhibitors in patients with psoriasis. METHODOLOGY: Researchers conducted a retrospective evaluation of 127 patients with psoriasis who discontinued an IL-17 inhibitor due to secondary failure and were directly switched to either …
Read More
Can Bimekizumab Match IL-23 Inhibitors in Psoriasis?
